Industry / Germany
Under-Prescribing Costing State Billions
February 2008 | Industry NewsAccording to a new study by the German Association of Research-Based Pharmaceutical Companies (VFA), the under-treatment of patients is costing Germany millions of euros each year. Although BMI acknowledges that the VFA has a vested interest, we also accept that there is some truth in this statement.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
